BioStem Technologies (OTCMKTS:BSEM) Announces Quarterly Earnings Results

BioStem Technologies (OTCMKTS:BSEM) released its earnings results on Thursday. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.24), Zacks reports. The business had revenue of $6.14 million during the quarter, compared to the consensus estimate of $5.70 million.

Here are the key takeaways from BioStem Technologies’ conference call:

• BioStem said Q1 marked a transformational shift to a hospital-focused business after its late-January acquisition, expanding its addressable market and adding a larger commercial infrastructure, hospital customers, and GPO contracts.
• Management reported minimal disruption from the acquisition, with hospital revenue of $5.4 million in the quarter and stable performance versus the acquired assets’ prior-year run rate. The company also said it retained the acquired sales team with limited turnover.
• BioStem is aggressively scaling its hospital sales force, growing to 35 direct reps plus more than 30 independent agents, and expects to reach 40 direct representatives by year-end. Management believes these hires will ramp through 2026 and into 2027.
• The company reaffirmed a path to gross margin expansion once it completes the Neox and Clarix technology transfer and brings manufacturing in-house, which it targets for the first half of 2027. Management said eliminating the current manufacturing markup should add roughly 7.5 margin points, with further upside from internal efficiencies.
• BioStem initiated full-year 2026 revenue guidance of $25 million to $29 million, with sequential growth expected through the year and the second half likely stronger than the first. The company also noted its confidential Form 10 filing as part of its Nasdaq uplisting effort.

BioStem Technologies Stock Performance

Shares of BioStem Technologies stock opened at $4.32 on Friday. BioStem Technologies has a one year low of $3.09 and a one year high of $14.52. The company has a market cap of $73.35 million, a PE ratio of -3.88 and a beta of 0.09. The business has a 50-day simple moving average of $4.82 and a 200-day simple moving average of $4.84.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on BSEM. HC Wainwright began coverage on BioStem Technologies in a research report on Wednesday, May 6th. They set a “buy” rating and a $9.00 price objective for the company. Zacks Research raised BioStem Technologies to a “hold” rating in a research report on Wednesday, March 18th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, BioStem Technologies has an average rating of “Buy” and a consensus price target of $9.00.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.